Jaroslav Bačovský
Impact in
- Hematology top 10%
- Multiple Myeloma Research and Treatments
-
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 46
- Multiple Myeloma Research and Treatments 46
- Oncology 26
- Bone health and treatments 10
- Peptidase Inhibition and Analysis 8
- Cancer Treatment and Pharmacology 7
- Co-authors
- Jiří Minařík (36 shared papers)Tomáš Pika (32 shared papers)Vlastimil Ščudla (22 shared papers)Marie Budı́ková (8 shared papers)Kateřina Langová (7 shared papers)Karel Indrák (5 shared papers)Ján Gurský (1 shared paper)Ladislav Dušek (2 shared papers)
In The Last Decade
Jaroslav Bačovský
46 papers receiving 193 citations
Peers
Comparison fields: 5 of 53
- Hematology 139
- Genetics 34
- Oncology 79
- Molecular Biology 102
- Neurology 15
Countries citing papers authored by Jaroslav Bačovský
This map shows the geographic impact of Jaroslav Bačovský's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaroslav Bačovský with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaroslav Bačovský more than expected).
Fields of papers citing papers by Jaroslav Bačovský
This network shows the impact of papers produced by Jaroslav Bačovský. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaroslav Bačovský. The network helps show where Jaroslav Bačovský may publish in the future.
Co-authors
The 25 scholars most cited alongside Jaroslav Bačovský, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 14 | |
| 2 | 2012 | 13 | |
| 3 | 2022 | 12 | |
| 4 | 2009 | 10 | |
| 5 | 2011 | 10 | |
| 6 | International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy. | 2006 | 10 |
| 7 | 2005 | 9 | |
| 8 | 2010 | 8 | |
| 9 | 2011 | 8 | |
| 10 | 2016 | 7 | |
| 11 | Multiple myeloma: predictive value of Tc-99m MIBI scintigraphy and MRI in its diagnosis and therapy. | 2008 | 6 |
| 12 | Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. | 2006 | 6 |
| 13 | 2022 | 5 | |
| 14 | 2010 | 5 | |
| 15 | 2005 | 4 | |
| 16 | 2008 | 4 | |
| 17 | 2009 | 4 | |
| 18 | 2002 | 4 | |
| 19 | 2010 | 4 | |
| 20 | 2018 | 4 |
About Jaroslav Bačovský
Jaroslav Bačovský is a scholar working on Hematology, Oncology, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 51 papers that have together received 198 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (46 papers), Bone health and treatments (10 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (8 papers), Peptidase Inhibition and Analysis (8 papers), Protein Degradation and Inhibitors (7 papers), Cancer Treatment and Pharmacology (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Chronic Lymphocytic Leukemia Research (5 papers). The work is most often cited by research in Hematology (139 citations), Genetics (34 citations), Oncology (79 citations), Molecular Biology (102 citations) and Neurology (15 citations). Jaroslav Bačovský has collaborated with scholars based in Czechia, Slovakia and Sweden. Frequent co-authors include Jiří Minařík, Tomáš Pika, Vlastimil Ščudla, Marie Budı́ková, Kateřina Langová, Karel Indrák, Ján Gurský, Ladislav Dušek, Pavel Moudrý and Jiří Bártek. Their work appears in journals such as Blood, European Journal Of Haematology, The Hematology Journal, Cell Death and Disease and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.